| __timestamp | Merus N.V. | Travere Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3852327 | 59644696 |
| Thursday, January 1, 2015 | 839656 | 79541000 |
| Friday, January 1, 2016 | 4478145 | 98015000 |
| Sunday, January 1, 2017 | 16432324 | 103958000 |
| Monday, January 1, 2018 | 11890871 | 103654000 |
| Tuesday, January 1, 2019 | 34110000 | 128951000 |
| Wednesday, January 1, 2020 | 35781000 | 135799000 |
| Friday, January 1, 2021 | 40896000 | 149883000 |
| Saturday, January 1, 2022 | 52200000 | 220206000 |
| Sunday, January 1, 2023 | 59836000 | 265542000 |
Unlocking the unknown
In the competitive world of biotechnology, understanding financial trends is crucial. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Merus N.V. and Travere Therapeutics, Inc. from 2014 to 2023. Over this period, Travere Therapeutics consistently outspent Merus N.V., with its SG&A expenses peaking at approximately 265% higher than Merus in 2023. Notably, Travere's expenses grew from around $60 million in 2014 to over $265 million in 2023, reflecting a strategic investment in growth and operations. Meanwhile, Merus N.V. saw a more modest increase, with expenses rising from about $3.9 million to nearly $60 million. This disparity highlights differing business strategies and market positions. As the biotech sector evolves, these financial insights offer a window into how companies allocate resources to drive innovation and market presence.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Merus N.V.
Comparing SG&A Expenses: Genmab A/S vs Merus N.V. Trends and Insights
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Merus N.V.
Operational Costs Compared: SG&A Analysis of Exelixis, Inc. and Merus N.V.
SG&A Efficiency Analysis: Comparing Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.
Veracyte, Inc. vs Merus N.V.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Merus N.V. or Galapagos NV
SG&A Efficiency Analysis: Comparing Mesoblast Limited and Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.